The potential impact is twofold. Scientifically, the LowLiteScope opens new frontiers for studying fast, 3D biological processes that are currently invisible due to light sensitivity or photon limitations, spanning neuroscience, developmental biology, and regenerative medicine. Societally, it provides a non-invasive and quantitative imaging tool that can accelerate discovery in health and disease, with clear translational opportunities in drug development and functional tissue assays.
To ensure further uptake, several needs remain: (i) continued research and engineering to refine optical designs into compact, plug-and-play modules, (ii) IPR and business development to protect key innovations and engage with potential industry partners, (iii) demonstrations with end-users to validate
performance in real-world biological applications, and (iv) access to finance and commercialisation pathways to transition from lab prototypes to scalable, user-friendly products.
Overview of results: By the end of this project, we delivered a working prototype of the LowLiteScope and the LUCID pipeline, demonstrated high-speed volumetric imaging in challenging biological contexts, and validated a new bioluminescent calcium indicator. Together, these results establish both the technical feasibility and the scientific impact of the technology, while providing a clear roadmap for translation into broader research and commercial applications.